Overview
Pharmaceutical companies make important life-saving medicines. But that shouldn't give them license to drive up drug prices, ignore the risks of harmful side effects, or block needed reforms in Congress and the states. Consider:
• Pharmaceutical companies use direct-to-consumer ads to sell their latest, most expensive drugs. The industry claims that these ads help to educate consumers, but a U.S. PIRG analysis of FDA records for the years 2001 to 2005 found that the ads for 150 different drugs were false or misleading.
• Merck, the manufacturer of Vioxx, continued to market its painkiller to doctors and patients years after the company had substantial evidence of increased the risk of heart problems. FDA researchers estimate that, in less than 5 years, Vioxx may have caused as many as 139,000 heart attacks and strokes.
• The industry continues to use unscrupulous marketing techniques to influence prescriptions that doctors write, including fancy meals, travel junkets and money—in the form of “consultant” fees.
• More than 3 million seniors are falling into the doughnut hole—Medicare’s prescription drug coverage gap. Seniors have to keep paying their monthly premiums, but Medicare does not pay for their drugs until seniors pay $3,600 in out-of-pocket expenses for their medicines. When Congress created the Medicare prescription drug benefit, the pharmaceutical industry and its lobbyists inserted a provision that prohibits the program from negotiating bulk-rate discounts for drugs.
• An overwhelming majority of Democrats (92 percent), Independents (85 percent) and Republicans (74 percent) support allowing Medicare to negotiate drug prices.
U.S. PIRG is working to change the industry-backed law. We supported the “Medicare Prescription Drug Price Negotiation Act, which overwhelmingly passed the House earlier this year. Unfortunately, the bill narrowly failed in the Senate. We are working to bring the bill up for another vote in the Senate.
